- Home
- SFST vs ZBIO Comparison
SFST vs ZBIO Comparison
Compare SFST & ZBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SFST
- ZBIO
- Stock Information
- Founded
- SFST 1999
- ZBIO 2019
- Country
- SFST United States
- ZBIO United States
- Employees
- SFST N/A
- ZBIO N/A
- Industry
- SFST Major Banks
- ZBIO
- Sector
- SFST Finance
- ZBIO
- Exchange
- SFST Nasdaq
- ZBIO NYSE
- Market Cap
- SFST 292.1M
- ZBIO 339.3M
- IPO Year
- SFST 1999
- ZBIO 2024
- Fundamental
- Price
- SFST $36.98
- ZBIO $7.85
- Analyst Decision
- SFST
- ZBIO Strong Buy
- Analyst Count
- SFST 0
- ZBIO 5
- Target Price
- SFST N/A
- ZBIO $31.75
- AVG Volume (30 Days)
- SFST 19.1K
- ZBIO 390.2K
- Earning Date
- SFST 01-28-2025
- ZBIO 02-16-2025
- Dividend Yield
- SFST N/A
- ZBIO N/A
- EPS Growth
- SFST N/A
- ZBIO N/A
- EPS
- SFST 1.73
- ZBIO N/A
- Revenue
- SFST $90,166,000.00
- ZBIO N/A
- Revenue This Year
- SFST N/A
- ZBIO N/A
- Revenue Next Year
- SFST $13.55
- ZBIO N/A
- P/E Ratio
- SFST $21.38
- ZBIO N/A
- Revenue Growth
- SFST 3.18
- ZBIO N/A
- 52 Week Low
- SFST $24.98
- ZBIO $7.50
- 52 Week High
- SFST $45.91
- ZBIO $26.25
- Technical
- Relative Strength Index (RSI)
- SFST 43.28
- ZBIO N/A
- Support Level
- SFST $35.48
- ZBIO N/A
- Resistance Level
- SFST $36.54
- ZBIO N/A
- Average True Range (ATR)
- SFST 1.02
- ZBIO 0.00
- MACD
- SFST -0.05
- ZBIO 0.00
- Stochastic Oscillator
- SFST 50.28
- ZBIO 0.00
About SFST Southern First Bancshares Inc.
Southern First Bancshares Inc is a bank holding company. The company engaged in the business of accepting demand deposits and savings deposits insured by the Federal Deposit Insurance Corporation (the "FDIC"), and providing commercial, consumer and mortgage loans to the general public of which a majority of the revenue is derived from the Commercial and Retail Banking segment which includes the provision of traditional deposit and lending products and services to its commercial and retail banking clients.
About ZBIO ZENAS BIOPHARMA INC
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.